Very much so, because we're seeing this situation obviously where vaccines globally, we were seeing sort of a hit to vaccine sales. Sanofi itself has said at the last quarter that its vaccine sales were down.

Sanofi will buy U.S. vaccines company Dynavax Technologies for around $2.2 billion (1.9 billion euros), expanding its vaccine portfolio, the French drugmaker said on Wednesday.

The cash deal seeks to strengthen the French drugmaker’s immunization portfolio after it suffered setbacks in clinical trials.

Sanofi ($SNY) said it will buy Dynavax Technologies ($DVAX) for about $2.2 billion in cash to grow its vaccines business. The French drugmaker

Sanofi has announced an agreement to acquire U.S.-based vaccines company Dynavax Technologies in an all-cash transaction valued at approximately $2.2 billion, marking another strategic move to expand its vaccines